Rapid Drug Desensitization Study in Adults Experiencing Hypersensitivity Reactions to Palynziq

Study of Phenoptin in Subjects With Phenylketonuria Who Participated in Protocols PKU-004 or PKU-006

Study to Evaluate the Effects of Kuvan on Individuals With Phenylketonuria (PKU) With Maladaptive Behaviors

Behavioral Effects of Kuvan in Children With Mild Phenylketonuria

Nutritional and Neurotransmitter Changes in PKU Subjects on BH4

Bone Mineral Density in Adults With Hyperphenylalaninemia on Kuvan Therapy

Biological Variation of Phenylalanine in Patients With Hyperphenylalaninemia

Safety and Therapeutic Effects of Sapropterin Dihydrochloride on Neuropsychiatric Symptoms in Phenylketonuria (PKU) Patients

Neurocognitive Outcomes in Mild Hyperphenylalaninemia (MHP)MHP Study

Safety and Tolerability Study of rAvPAL-PEG to Treat Phenylketonuria

Kuvan® in Phenylketonuria Patients Less Than 4 Years Old

The Effects of Kuvan on Functional Brain Connectivity in Individuals With Phenylketonuria (PKU)

Sapropterin on Cognitive Abilities in Young Adults With Phenylketonuria

Sapropterin in Individuals With Phenylketonuria

Dose-Finding Study to Evaluate the Safety, Efficacy, & Tolerability of Multiple Doses of rAvPAL-PEG in Subjects With PKU

Safety, Tolerability, and Efficacy Study of rAvPAL-PEG Administered Daily in Subjects With Phenylketonuria (PKU)

An Open-Label Phase 3 Study of BMN 165 for Adults With PKU Not Previously Treated w/ BMN 165

A Study to Evaluate Subcutaneously Administered rAvPAL-PEG in Patients With Phenylketonuria for 24 Weeks

A Phase 3 Substudy to Evaluate Executive Function in Adults With PKU Who Are Participating in the Phase 3 Study, 165-302

Effect of Kuvan on Neurocognitive Function, Blood Phenylalanine Level, Safety, and Pharmacokinetics in Children With PKU